A Multi -Center, Randomized, Parallel-Group, Placebo-Controlled, Safety Assessor-Blinded Trial, Evaluating the Safety and Efficacy of Sugammadex in Cardiac Patients
Latest Information Update: 09 May 2022
At a glance
- Drugs Sugammadex (Primary) ; Rocuronium bromide
- Indications Neuromuscular blockade
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GLOW
- Sponsors NV Organon
Most Recent Events
- 26 Sep 2014 New trial record